HCV and Porphyria Cutanea Tarda: A Strong Epidemiological Association
HCV infection is strongly associated with porphyria cutanea tarda (PCT), particularly the sporadic form (Type I), where HCV acts as a major triggering factor rather than a direct causative agent, with prevalence rates ranging from 8-10% in Northern Europe to 71-91% in Southern Europe 1.
Pathophysiologic Mechanism
The relationship between HCV and PCT operates through an indirect mechanism involving multiple factors:
- Enzyme deficiency: PCT results from 50% deficient activity of uroporphyrinogen decarboxylase (URO-D) in the liver 1
- Iron overload as the critical event: Hepatic siderosis disrupts URO-D enzymatic activity by inducing formation of an intracellular inhibitor 1
- HCV's role: The virus appears to enhance an oxidative environment around URO-D and facilitates iron accumulation through hepcidin down-regulation 2
A crucial caveat: The absence of altered porphyrin metabolism in HCV-positive patients without PCT argues against a direct causative role of HCV 1. This explains why PCT develops in only a minority of HCV-infected patients—likely those with additional susceptibility factors related to iron homeostasis 2.
Clinical Presentation
PCT manifests with:
- Cutaneous lesions in sun-exposed areas
- Photosensitivity and skin fragility
- Facial hypertrichosis
- Late-stage sclerodermoid plaques 1
Geographic Variation and Prevalence
The association shows striking geographic differences:
- Southern Europe: 71-91% of PCT patients are HCV-positive 1
- Italy: 76-82% prevalence 3
- Stockholm, Sweden: 36.4% in sporadic PCT 4
This geographic variation likely reflects regional HCV prevalence patterns 1.
Treatment Implications
Standard PCT Management
First-line treatment includes:
- Photo-protection
- Phlebotomy to reduce hepatic iron stores
- Anti-malarial drugs (chloroquine) 1
HCV-Specific Considerations
For interferon-based therapy (now largely obsolete): Controversial results occurred because:
- Effective antiviral therapy could improve PCT when preceded by therapeutic phlebotomy 1
- However, ribavirin-induced hemolytic anemia could worsen or trigger new-onset PCT by increasing liver iron excess 1, 5
For direct-acting antivirals (DAAs):
- Viral eradication with DAAs leads to rapid PCT resolution and disappearance of urinary porphyrins 6, 2
- This striking response contrasts with the decades-long delay between HCV infection and PCT onset, supporting HCV's role in maintaining the oxidative environment 2
- Avoid DAAs known to cause photosensitivity 1
Clinical Algorithm
- Screen all PCT patients for HCV infection 4—the infection may be clinically silent
- If HCV-positive with active PCT:
- Check for additional risk factors:
Important Pitfall
Age at onset: HCV-positive PCT patients develop disease at a significantly younger age than HCV-negative patients 9, suggesting HCV is a major triggering factor that accelerates disease manifestation in susceptible individuals.